DGAP-Ad-hoc: PAION AG / Key word(s): Miscellaneous PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION 29-Jan-2021 / 11:20 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO (R) (REMIMAZOLAM) IN PROCEDURAL SEDATION - Positive CHMP opinion based on the data from a comprehensive clinical program in procedural sedation in adult patients undergoing bronchoscopy or colonoscopy - Final decision on MAA expected in the first half of 2021